drugset / Trial / NCT01863199

Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)

NCT01863199

RandomizedParallel-groupOpen-labelTreatment

Summary

A study to use in home technology to reduce the burden of in office visits and injections.

Timeline

Start
2013-05
Primary completion
2015-11
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranibizumab Monoclonal antibody 0.5 mg Intravitreal